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FS (%) 43±7 44±6 47±5 32±7*† 
LVEDD (mm) 3.2±0.3 3.3±0.2 3.1±0.3 3.5±0.1 
LVESD (mm) 1.8±0.3 1.8±0.1 1.7±0.2 2.3±0.2‡§ 
 
Baseline: prior injection with respective adenovirus (i.v. via the tail vein). Fractional 
shortening (FS), left ventricular end-diastolic diameter (LVEDD), left ventricular end-systolic 
diameter (LVESD), and heart rate were determined by echocardiography, heart rate was 
similar in both groups at baseline or 14 days after adenovirus injection (data not shown). 
*P<0.05, §P<0.01 vs. corresponding baseline group; †P<0.05, ‡P<0.01 16K-Ad vs. Control-
Ad 14 d after injection, n=5 per group, all male mice 12 weeks of age. 
 
Supplemental Table 2: Follow up of patients with PPCM treated with standard therapy 
for heart failure and bromocriptine 
 
 PPCM baseline (n=7) Follow up with BR 
treatment (n=7) 
p value  
LVEF (%) 21±13 (range 9-45) 52±16 (range 30-76) 0.0044** 
LVEDD (mm) 60±7 (range 51-67) 55±7 (range 47-66) 0.1376 
 
Baseline: at time of initial diagnosis prior to bromocriptine (BR) treatment (6.5±5 months). 
Left ventricular ejection fraction (LVEF) and left ventricular end-diastolic diameter (LVEDD) 
were determined by echocardiography. ** Comparing the change from baseline to 5 months 




Supplementary Data  
 
Treatment with recombinant Neuregulin-1 attenuates PPCM in CKO mice 
To assess the importance of impaired ErbB signaling for the development of PPCM, 
CKO mice were injected with recombinant NRG1 spanning 2 pregnancies and nursing 
periods. Dose-response analysis indicated that 1.25 μg i.p. was sufficient to activate ErbB 
signaling in the heart as indicated by activation of ERK1/2 (Figure S4N). This dose, daily 
applied for two subsequent nursing periods moderately attenuate cardiac dysfunction 
compared to NaCl treated CKO mice (Figure 4N).  
 
Supplemental methods  
 
RNA extraction, miRNA, pri-miR, mRNA expression analysis by TaqMan MicroRNA 
Assay and Quantitative Real-time PCR Analysis 
 
Total RNAs were extracted with the miRNeasy kit (Qiagen). Taqman methods were 
used to assess miRNA expression. Briefly, 10 ng RNA was reverse transcribed to cDNA with 
the Taqman microRNA Reverse Transcription kit and the Taqman microRNA assay stem 
loop primers (Applied Biosystems). Resulting cDNAs were used for quantitative real-time 
PCR using Taqman microRNA assay and Taqman universal PCR master mix reagents 
(Applied Biosystems). Thermal cycling was performed on an Applied Biosystem 7900 HT 
detection system (Applied Biosystems). The relative miRNA levels were normalized to two 
internal controls, RNU-44 or RNU-48 for human cells and sno-202 for rat cells. The relative 
miRNA levels were normalized to two internal controls, sno-135 and sno-202 (Applied 
Biosystems) for mouse tissues. For the plasma and exosomes, the relative miRNA levels were 
normalized to two spikes-in miRNAs: cel-miR-39 and cel-miR-238 (Applied Biosystems).  
 
For mRNA expression analysis, RNAs were extracted with the miRNeasy kit (Qiagen) 
according to the manufacturer’s protocol. cDNA synthesis was performed with 1 µg total 
RNA and the iScript cDNA Synthesis Kit (BioRad) according to the manufacturer’s 
instructions. Resulting cDNAs (20 ng) were used for quantitative real-time PCR using the 
SYBR green method (Roche Applied Sciences). Thermal cycling was performed on an ABI 
Prism 7900 HT Sequence Detection System (Applied Biosystems). For all reactions, no-
template controls were run, and random RNA preparations were also subjected to sham 
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reverse transcription to check for the absence of genomic DNA amplification. Quantitative 
real-time PCR was performed with SYBR green method (Bioline and Thermo Fisher 
Scientific). Thermal cycling was performed on an Applied Biosystem 7900 HT detection 
system and a Stratagene MX3005P multiplex QPCR system (Applied Biosystems and 
Stratagene). The relative transcript level of each gene was normalized to the housekeeping 
genes cyclophilin-A (PPIA), beta-2 microglobulin (B2M) and/or GAPDH. Primers were 
designed using Primer Express software and selected to span exon-exon junctions to avoid 
detection of genomic DNA (primer sequences are provided below). 
For pri-miR expression analysis, cDNA was produced as described above. Resulting cDNAs 
(20 ng) were used for quantitative real-time PCR using Taqman pri-miR assay (Applied 
Sciences). 
Northern blot analysis 
Total RNA from pre-miR-146a and pre-miR-ctrl transfected cardiomyoctes was isolated 
using Trizol (Life Technologies) after 5 days. RNA (10 µg) was electrophoresed in an 16% 
denaturing polyacrylamide gel and transferred by electroblotting onto Hybond-N membranes 
(Amersham Pharmacia Biotech, Piscataway, NJ). Hybridization and washing were carried out 
at 37° C according to standard protocols. Membranes were probed with a 
32
P-labeled 22-nt 
miR-146a LNA oligonucleotide with the following sequence 5’-
AACCCATGGAATTCAGTTCTCA-3’ (Exiqon, Vedbaek, Denmark) and were subsequently 
visualized by autoradiography. Serial dilutions (1 to 0.01 µmol/l) of the synthetic miR-146a 
RNA (5’-UGAGAACUGAAUUCCAUGGGUU-3’, BioSprings, Frankfurt, Germany) were 
subjected to the gel.  Endogenous U6 snRNA served both as an internal size standard and a 
loading control (U6sn LNA probe: 5’-CACGAATTTGCGTGTCATCCTT -3’, Exiqon).   
Construction of S-miR-146a-IEW lentiviral vector 
To construct the lentiviral vector S-miR146a-IEW containing the miR-146a, the 
plasmid SIEW was digested with BamHI followed by a DNA polymerase I fill-in reaction and 
gel purification. The miR-146a cassette was excised from pEP-miR-146a plasmid with NheI 
and BamHI, and the cohesive ends were filled in using Klenow. The blunt-end fragment was 
ligated with the blunted BamHI vector fragment placing miR-146a downstream of the SFFV 
promoter (SmiR-146a-IEW). The preparation of recombinant lentiviral supernatants were 
performed as described earlier (1). 
 
Transduction of miR-146a and Immunoprecipitation of Human Argonaute 2 Complexes 
with the RIP kit 
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Lentiviral supernatants expressing miR-146a and control vector SIEW were used to 
transduce approximately 1x10
7
 NRCM cells with an MOI of ~2. Cells were scraped off 96 h 
after transduction with either miR-146a or control vector. microRNA:mRNA 
immunoprecipitation was performed using the Magna RIP kit (Millipore, Billerica, MA, 
USA) following the manufacturer’s protocol. For RISC-IPs of NRCM, 1x107 cells were taken 
for each replicate, washed in PBS before lysis in 100 µl complete RIP-lysis buffer and 
incubated with magnetic beads conjugated with anti-Ago2/eIF2C2 antibody (Abcam, 
Cambridge, UK) control normal mouse IgG (Millipore) and rotated overnight at 10°C. Co-
immunoprecipitated RNA, including miRNA:mRNA complexes was subjected to qRT-PCR 
and miR-qRT-PCR. Expression of mature miRNAs was determined by miR-qRT-PCR using 
miRNA-specific looped RT-primers and TaqMan probes as recommended by the 
manufacturer (Applied Biosystems). Normalization was performed using the 2-ΔΔCT method 
relative to U6snRNA. 
 
Microarray Experiment 
Microarray experiments have been performed by the GIGA Genomics Facility (Liège, 
Belgium). After transfection with 50 nM of pre-miR-146a or pre-miR-control for 24 h, total 
RNA was isolated from HUVECs using RNeasy Mini Kit (Qiagen). Extracted RNA yields 
were determined using a NanoDrop® ND-1000 spectrophotometer (Thermo Fisher 
Scientific). The purity and quality of extracted RNAs were evaluated using the Experion RNA 
StdSens Analysis kit (Bio-Rad). High quality RNAs with RNA Quality Indicator (RQI) score 
greater than 8 were used for microarray experiments. Gene expression profiling was 
performed using Illumina’s multi-sample format Human Ref-8 BeadChip that contains 24,500 
transcripts and profiles eight samples simultaneously on a single chip (Illumina Inc.). For each 
sample, 250 ng of total RNA were labeled using an Illumina TotalPrep RNA Amplification 
kit (Ambion) according to the manufacturer’s instructions. Briefly, double-stranded cDNAs 
were synthesized using T7-oligo (dT) primers and followed by an in vitro transcription 
reaction to amplify cRNAs while biotin was incorporated into the synthesized cRNA probe. 
The cRNA probe was then purified and quantified using a NanoDrop® ND-1000 
spectrophotometer (Thermo Fisher Scientific). Biotinylated cRNA probe was hybridized to 
the Human Ref-8 BeadChip Array (Illumina). Labeled cRNAs (750 ng) were used for 
hybridization to each array. The hybridization, washing, and scanning were performed 





Microarray Data Analysis 
The microarray images were registered and extracted automatically during the scan 
according to the manufacturer’s default settings. Raw microarray intensity data were analyzed 
with the GenomeStudio software normalized using the quantile normalization method 
according to the manufacturer’s recommendation. Differential analysis were performed for 
each group and data were filtered on Differential Score higher than 30 or lower than – 30. The 
probes were considered as expressed by filtering data on Detection P-value lower than 0.01. 
Data were further analyzed using Ingenuity Pathway software. Microarray data have been 
deposited in Gene Expression Omnibus (GEO) database (accession number GSE43016). 
 
Sylamer analysis 
Sylamer analysis was used to analyze miRNA binding site differences in 3’UTR 
regions of human genes (2). The analysis was performed on the data generated from the 
microarray data analysis (see above). The mRNA gene list was ranked from most to the least 
down-regulated genes and uploaded into SylArray (www.ebi.ac.uk/enright-srv/sylarray). 
 
Preparation of cell extracts  
Cells were washed twice with cold PBS and scraped into lysis buffer [25 mM HEPES 
(pH 7.9), 150 mM NaCl, 0.5 % Triton, 1 mM dithiothreitol, 1 mM 
phenylmethylsulfonylfluoride] on ice. Insoluble cell debris was removed by centrifugation at 
10,000 g for 15 min. Aliquots of protein-containing supernatant were stored at -80 °C. Protein 
concentrations were determined by the Bradford method, with the Bio-Rad protein assay 
reagent (Bio-Rad Laboratories).  
 
Western Blot Analysis 
Soluble cell lysate (30 μg) was resolved by SDS-PAGE (12 %) and transferred to a 
polyvinylidene fluoride membrane (Milipore Corp.). Blots were blocked overnight with 8 % 
milk in Tris-buffered saline with 0.1 % Tween 20 and probed for 1 h with primary antibodies: 
anti-p65 (sc-109, Santa Cruz Biotechnology), anti-beta-actin (ab8226, Abcam), anti-NRAS 
(sc-31, sc-209, Santa Cruz), anti-ERBB4 (4795S, Cell Signaling), anti-ERK (9102, Cell 
Signaling), anti-phospho-ERK (9101S, Cell Signaling) and anti-beta-tubulin (ab6046, 
Abcam). After three washes with Tris-buffered saline containing 0.1 % Tween 20, antigen-
antibody complexes were detected with peroxidase-conjugated secondary antibody and an 
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enhanced fluoro-chemiluminescent system (ECL; Pierce Biotechnology). Ponceau red 
staining was used to control sample loading and for normalization of animal blots. 
Quantifications were performed using Image J software and are presented in bar graph 
normalized to the level of corresponding loading control (beta-tubulin, beat-actin or Ponceau 
red). 
 
NF-κB Binding Activity 
The p65 DNA-binding activity of NF-κB was quantified by ELISA (EZ Transcription 
Factor kit NF-κB p65 (Pierce)) according to manufacturer’s instructions on total protein 
extracts. NF-κB binding to the target oligonucleotide was detected by incubation with primary 
antibody, specific for the activated form of p65, visualized by anti-IgG horseadish peroxidase 
conjugate and developing solution. Chemiluminescence was quantified with a luminometer.  
 
Luciferase Assay (3'UTR reporter assays) 
 HEK293T cells were transfected with 30 pmol of pre-miR-Ctrl or pre-miR-146a with 
0.6 μl of DharmaFECT-4 (Dharmacon Research Inc). The next day, cells were transfected 
with 25 ng of the psiCHECK2 vector (Promega) expressing the 3’UTR of human NRAS 
mRNA (Imagene) or the mutated 3’UTR of human NRAS mRNA (QuickChange II Site-
Directed Mutagenesis Kit, Agilent) with JET-PEI (Polyplus transfection) following 
manufacturer’s instructions. Wild-type region of 3’UTR human NRAS mRNA binding seed 
sequence of miR-146a: 5’-AGUUCUCA-3’. Mutated region of 3’UTR human NRAS mRNA 
binding seed sequence of miR-146a: 5’-UGUUCAUG-3’. Forty-eight hours later, luciferase 
assay was performed using Dual-Luciferase Reporter Assay System (Promega). Renilla 
luciferase activity was normalized to Firefly luciferase.  
 
Luciferase Assay (promoter reporter assays). 
 The 600bp sequences containing the two NF-ĸB binding sites wildtype or mutated (3) 
were synthesized (Genescript) and cloned into the pGL3 reporter vector (Promega) in the 
HindIII et XhoI sites, located upstream of the Firefly Luciferase coding sequence. HUVEC 
(80,000/well in 12-well plates) were transfected with 1 µg of the vector and 0.025 µg of the 
control vector pRenilla-Luc using XTreme Gene HP (Roche). After 24 h, cells were treated 
with 16K-PRL (50 nM). Forty-eight hours later, luciferase assay was performed using Dual-
Luciferase Reporter Assay System (Promega). Firefly luciferase activity was normalized to 




Cell proliferation.  
Control and NRAS siRNA-transfected cells or pre-miR/anti-miR-transfected cells 
were plated in 96-well culture plates at a density of 10,000 cells per well in 100 µl of SFM 
(Lonza) supplemented with 5 ng/ml bFGF or EGM-2 (Lonza) and 0.5 % serum, respectively 
and incubated for 72 h. When indicated, the cells were treated with bFGF (10 ng/ml), with or 
without 16K PRL (50 nM). Proliferation was analyzed 24 h later by measuring BrdU 
incorporation using the Cell Proliferation ELISA, BrdU (Colorimetric) (Roche).  
 
Caspase-3 activity assay 
 Control and NRAS siRNA-transfected cells or pre-miR/anti-miR-transfected cells 
were plated in 24-well culture plates at a density of 20,000 cells per well in 500 µl of SFM 
(Lonza) supplemented with 5 ng/ml bFGF or EGM-2 (Lonza) and 0.5 % serum, respectively. 
Caspase-3 activity was measured 48 h post-transfection with the CaspACE Assay System 
Fluorimetric (Promega Corp., Madison, WI) according to the manufacturer’s instructions. 
 
Flow cytometry 
 Transfected cells or pre-miR/anti-miR-transfected cells were plated in 6-well culture 
plates at a density of 100,000 cells per well in 500 µl of SFM (Lonza) supplemented with 5 
ng/ml bFGF or EGM-2 (Lonza) and 0.5 % serum, respectively. Cells were stained with 
Annexin-V FITC and propidium iodide (PI) with FITC Annexin-V Apoptosis detection kit II 
(BD Pharmingen) according to the manufacturer’s instructions. 
 
DNA Fragmentation ELISA  
Control and NRAS siRNA-transfected cells or pre-miR/anti-miR-transfected cells 
were plated in 24-well culture plates at a density of 100,000 cells per well in 500 µl of SFM 
(Lonza) supplemented with 5 ng/ml bFGF or EGM-2 (Lonza) and 0.5 % serum, respectively 
and incubated for 72 h. DNA fragmentation was measured with the Cell Death
plus
 Detection 
ELISA kit (Roche Molecular Biochemicals) according to the manufacturer's instructions.  
 
Scratch wound migration assay 
Pre-miR/anti-miR-transfected cells were plated in 48-well culture plates at a density of 
50000 cells per well in 350 µl of EBM-2 (Lonza) and 0.5 % serum and incubated for 24 h to 
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reach confluence. Using a tip, a wound was made in the monolayer (at time 0). The cells were 
then washed with PBS and incubated with EBM-2 medium containing 10 ng/ml recombinant 
bFGF (Promega Corp.) and 50 ng/ml recombinant VEGFa (RELIATech GmbH) for 16 h. The 
distance between the two sides of the wound was measured with a graduated ocular lens 
coupled with an Olympus CKX41 microscope (Olympus). The distance between the two sides 
of the wound after 16 h of migration was subtracted from the distance at time 0 and 
represented on a graph. 
 
Capillary tube network formation on a Matrigel matrix (tubulogenesis assay) 
Pre-miR/anti-miR-transfected cells were plated in 96-well culture plates pre-coated 
with 50 µl Matrigel per well (BD Biosciences) at a density of 10000 cells per well in 100 µl 
of EGM-2 (Lonza). The cells were incubated for 16 h. Pictures were taken with an Olympus 
fluorescence microscope (Olympus). Quantitative analysis of network structure was 
performed with ImageJ software (http://rsbweb.nih.gov/ij/) by counting the number of 
intersections in the network and measuring the total length of the structures.  
 
Exosome purification, labeling and analysis 
Exosomes were purified from conditioned cell culture media as previously described 
(4). Briefly, medium was collected and centrifuged at 300 g for 15 min and then again at 
12,000 g for 35 min. Supernatants were then passed through a 0.22 µm filter (Millipore) and 
ultracentrifuged at 110,000 g for 70 min at 4 °C. The pellets were washed with PBS and after 
a second ultracentrifugation at 110,000 g for 70 min at 4 °C, pellets of exosomes were 
resuspended in PBS. Exosomes were labeled and analyzed by flow cytometry as previously 
described (5). Briefly, exosome preparations were incubated with 4-mm-diameter 
aldehyde/sulfate latex beads (Invitrogen) and resuspended in PBS containing 2% FCS. 
Exosome-coated beads were incubated with anti-CD63-FITC (Pharmingen), followed by 
incubation with FITC-conjugated secondary antibody and analyzed on an FACS analyzer 
(Beckman Coulter). For the fusion experiments, exosomes were stained using the PKH67 
Green Fluorescent Cell Linker Mini Kit according to manufacturer’s instructions (Sigma-
Aldrich). For the dynamic light scattering, the exosomes were suspended in PBS and analyses 
were performed with a Zetasizer Nano ZS ‘Malvern Instruments Ltd). Intensity, volume and 




NRCM were transfected with anti-miR-146a or anti-miR control (100 nM, Ambion) 
using Lipofectamine (Invitrogen). After transfection for 24 h, cells were washed, treated with 
exosomes loaded with miR-146a or control exosomes (40ug/ml) and kept for an additional 4 
days in serum-free medium. Cells were harvested or cell metabolism was determined by MTS 
assay (Promega) according to manufacturer’s instruction. Cell culture experiments were 
performed from 3 independent cell isolations 
 
Dynamic light scattering 
 Exosomes were suspended in PBS and dynamic light-scattering measurements were 
performed with a Zetasizer Nano ZS (Malvern Instruments Ltd). Intensity, volume and 
distribution data for each sample were collected on a continuous basis for 4 min in sets of 
three. 
 
Immunhistochemistry of exosomes in vivo 
Fifty µg of exosomes or control solution were injected directly into the heart at three 
different injection points in adult female WT mice (n=2). The animals were euthanized 24 h 
post-injection. The hearts were extracted, fixed in 2 % paraformaldehyde (PFA), washed in 
PBS and then incubated in 15 % and 30 % sucrose. Fixed hearts were cryo-sectioned and 
stained with anti-human CD63 (Abcam ab134045) antibody, sarcomeric α-Actinin (A7811, 
SIGMA) and DAPI Hoechst 33258 (SIGMA). Images were taken by fluorescence microscopy 
with Axiovision 4.6 software (Carl Zeiss).   
 
In situ hybridization and immunohistochemistry 
On LV cryosections, H&E, isolectin B4 (Vector), wheat germ agglutinin (WGA, 
Vector), CD31 (BD Pharmingen, 555289) and Hoechst 33258 stainings were performed as 
described (6). In situ hybridization for miR-146a was performed using a 5’ fluorescein labeled 
19mer antisense oligonucleotide (Ribotask) containing locked nucleic acid and 2’OME RNA 
moieties (FAM-AacCcaTggAauTcaGuuCucA, capitals indicate LNA, lower case indicates 
2’OME RNA). The hybridizations were done on 6-µm cryosection according to protocol 
previously described (7) with a hybridization temperature of 60°C. As control, a mutated 
miR-146a probe (FAM-AcaCacTccAaaTguGuuCauG) was used and gave no specific signal.  
 
Electronic Microscopy analysis 
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NRCM were treated with exosomes (final concentration 20 µg/ml) dissolved in NaCl 
or control solution. After 16 h pre-incubation, the NRCMs were washed with PBS and fixed 
in 2,5 % glutaraldehyde/ 1 % paraformaldehyde in 0.1 M sodium phosphate buffer (pH 7.4) 
for 2 h at 4°C. Then the cells were washed 3 times in sodium phosphate buffer for 10 min at 4 
°C and post-fixed for 30 min with 2 % osmium tetroxide. After dehydration in graded ethanol, 
samples were embedded in Epon. Ultrathin sections obtained with a Reichert Ultracut S 
ultramicrotome were contrasted with uranyl acetate and lead citrate. Observations were made 
with a Jeol JEM-1400 transmission electron microscope at 80 kV.  
 
Sequences of qRT-PCR primers, siRNAs and antagomir 
All primers and siRNA and scramble siRNA control were synthesized by IDT-DNA 
 
Gene Sense primers (5' to 3') Antisense primers (5' to 3') 
hsa p65 AATCCAGTGTGTGAAGAAGCGG TAGTCCCCACGCTGCTCTTCTA 
hsa NRAS ATTTTTCCCGGCTGTGGTC CCAACCACCACCAGTTTGTACT 
hsa IRAK1 TCTACCAAGCCAGGCCCAGA TCCGAGAAGTTGTGGGTGCC 
hsa PPIA CCAACACAAATGGTTCCCAGT CCATGGCCTCCACAATATTCA 
hsa B2M GAGTATGCCTGCCGTGT AATCCAAATGCGGCATCT 
hsa ErbB4 GATTCTCAGTCAGTGTGTGCAGGAAC TATCTCCAGGTTGCCCATGACAACC 
mmu/rno ErbB4 GTGCTATGGACCCTACGTTAGT TCATTGAAGTTCATGCAGGCAA 
mmu NRAS CTGGCCAAGAGTTACGGAATTC CATTCGGTACTGGCGTATCTCC 
mmu/rno PPIA ACCGTGTTCTTCGACATCACG CTGGCACATGAATCCTGGAATA 
mmu/rno IRAK1 TCCTCCACCAAGCAGTCAAG AAAACCACCCTCTCCAATCCT 
mmu/rno Notch1 CCGTGTAAGAATGCTGGAACG AGCGACAGATGTATGAAGACTCA 
mmu/rno GAPDH ACCACCATGGAGAAGGCTGG CTCAGTGTAGCCCAGGATGC 
mmu/rno b2m CATGGCTCGCTCGGTGACC AATGTGAGGCGGGTGGAACTG 
 
 
Nom Brin sens Brin anti-sens 







rArGrC rUrUrA rCrUrG rArUrA rArArC 
rCrUrA rArUrA rUrUC A 
rUrGrA rArUrA rUrUrA rGrGrU rUrUrA 






rGrGrC rArGrU rCrArC rArArA rUrUrA 
rArCrA rUrGrU rUrGC T 
rArGrC rArArC rArUrG rUrUrA rArUrU 
rUrGrU rGrArC rUrGrC rCrGrG 
siRNA control 
(NRAS) 
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